Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

Abstract

Background The aim of the present study was to evaluate the effects of curcumin supplementation on inflammatory indices, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD). Methods Fifty patients with NAFLD were randomized to receive lifestyle modification advice plus either 1500 mg curcumin or the same amount of placebo for 12 weeks. Results Curcumin supplementation was associated with significant decrease in hepatic fibrosis ( p < 0.001), and nuclear factor-kappa B activity ( p < 0.05) as compared with the baseline. Hepatic steatosis and serum level of liver enzymes, and tumor necrosis-α (TNF-α) significantly reduced in both groups ( p < 0.05). None of the changes were significantly different between two groups. Conclusion Our results indicated that curcumin supplementation plus lifestyle modification is not superior to lifestyle modification alone in amelioration of inflammation. Trial registration IRCT20100524004010N24 , this trial was retrospectively registered on May 14, 2018.

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

“…Nevertheless, absent histological evaluation of changes following curcumin treatment strongly limits impact of the studies especially in terms of their anti-fibrotic capacity [379,380]. Moreover, a recent placebo-controlled clinical trial investigating lifestyle modification plus curcumin supplementation vs. placebo in 50 patients with NASH did not find significant advantages of curcumin in amelioration of biochemical and sonographic liver inflammation, steatosis, and fibrosis compared to lifestyle intervention alone [381]. Well-designed randomized placebo-controlled trials including histological examination are needed to define curcumin's significance in clinical practice.…”

Knockout of calpain‐1 protects against high‐fat diet‐induced liver dysfunction in mouse through inhibiting oxidative stress and inflammation

“…Hyperlipidemia induces the lipid accumulation in liver, resulting in the liver dysfunction (Qi et al., 2019; Ramos et al., 2020; Saadati et al., 2019). To investigate the mechanism underlying the protection against liver dysfunction by knockout of calpain‐1, the lipid profiles in serum and liver were determined.…”

Medicinal Plants as a Potential and Successful Treatment Option in the Context of Atherosclerosis

“…Panahi Y et al also observed lipid-lowering effect in their randomized controlled trial using curcuminoids (1 g/ day plus piperine 10mg/day) treatment of diabetes patients for 12 weeks (Panahi et al, 2018). Finally, a treatment with amorphous dispersion curcumin formulation (500 mg/day equivalent to 70mg curcumin) of non-alcoholic fatty liver patients for 8 weeks resulted in BMI-reduction as well as plasma Tg, LDL, and glucose levels lowering (Saadati et al, 2019). In the placebo-controlled clinical study of the effect of 1-year licorice root extract consumption on cardiovascular risk factors, beneficial results were demonstrated, namely, the significant reduction of TC and LDL levels as well as hypotensive activity (Fogelman et al, 2016).…”

“…Phytoestrogens are characterized by lipid-lowering and hypotensive effects. Villa P et al in their pilot randomized trial involving ninety women in menopausal transition showed that administration of phytoestrogen substances in addition to vitamins and passionflower herbal preparation during 6 months led to TC decrease in blood plasma (Saadati et al, 2019). Eight-week of soy nut diet helped to decrease of fasting blood glucose as well as to improve blood lipids profile, significantly decreasing TC and LDL (Fogelman et al, 2016).…”

“…-Regulating LXR/PPAR-ABCA1 pathway (Zhao S. et al, 2016) -Up-regulation of LXRa and ABCA1 expression (Zhao et al, 2014) Hypotensive effects Garlic (Allium sativum L.) -Inhibition of angiotensin-converting enzyme (Asdaq and Inamdar, 2010) -Activation of the growth suppressor p27 (Castro et al, 2010) -Down-regulation of angiotensin II receptor (Mansour et al, 2013) -Reduction of vasoconstrictor prostanoids synthesis (Al-Qattan et al, 2001) -Stimulation of H2S production (Al-Qattan et al, 2006) -Regulation of endothelial NO synthesis (Ried and Fakler, 2014;Karagodin et al, 2016b) 2018Allicor (Allium sativum L.) 4-week randomized, double-blind, placebo-controlled trial in 42 men: -lipid-lowering effect (TC -7.6 ± 2.4%, LDL -11.8 ± 4.5%, Tg -7.7 ± 9.0%) Sobenin et al (2008a) 16-weeks randomized, placebo-controlled, double-blind trial in 84 men with moderate hypertension: -hypotensive (SBP -9.3 ± 0.7 mmHg, DBP -3.8 ± 0.5 mmHg) Sobenin et al (2009) 4-weeks randomized double-blinded placebo-controlled outpatient clinical trial of 60 T2D patients: -blood glucose decrease (-1.8 ± 0.5mmol/l) Sobenin et al (2008) Garlic (Allium sativum L.) 6-weeks randomized, double-blind, placebo-controlled trial in 51 patients with obesity: -LDL-lowering effect (p=0.05) Curcumin formulation 3-months randomized double-blind placebo-controlled trial in 100 T2D patients: -blood glucose decrease, -9 ± 16 mg/dL Panahi et al (2018) 12-weeks randomized, placebo-controlled trial in 50 patients with non-alcoholic fatty liver disease -BMI decrease (p < 0.001) -TNF-a reduction (< 0.001) Saadati et al (2019) Licorice root extract 12-months randomized placebo-controlled study in 110 patients with hypercholesterolemia: -lipid-lowering effect (TC -7.8%, LDL -4.9%)…”